Table 1.
Baseline characteristics of twenty participants treated with halo fixation and radiotherapy.
| Patients (N=20) | |
|---|---|
| Gender, n (%) | |
| Male | 9 (45 %) |
| Female | 11 (55 %) |
| Age | |
| Median (range) | 61 (45–82) |
| Primary cancer site, n (%) | |
| Breast | 6 (30 %) |
| Multiple myeloma | 5 (25 %) |
| Prostate | 4 (20 %) |
| Lung | 1 (5 %) |
| Other* | 4 (20 %) |
| SINS score, n (%) | |
| SINS 8–12 | 3 (15 %) |
| SINS 13 | 5 (25 %) |
| SINS 14 | 5 (25 %) |
| SINS 15 | 5 (25 %) |
| SINS 16–17 | 2 (10 %) |
| Radiation treatment | |
| 8 Gy in 1 fraction | 5 (25 %) |
| 30 Gy in 10 fractions | 10 (50 %) |
| Other fractionation scheme | 5 (25 %) |
| KPS, n (%) | |
| 50 | 6 (30 %) |
| 60–70 | 6 (30 %) |
| 80–100 | 8 (40 %) |
| ASIA Impairment Scale, n (%) | |
| ASIA D | 7 (35 %) |
| ASIA E | 13 (65 %) |
| Pain score before halo-fixation | |
| Median (range) | 8 (0–10) |
| Missing | 4 |
| Use of dexamethason, n (%) | |
| Yes | 16 (80 %) |
| No | 4 (20 %) |
SINS: Spinal instability neoplastic score, KPS: Karnofsky performance score, ASIA: American Spinal Injury Association
*other histologies included vaginal cancer, urothelial carcinoma and cholangiocarcinoma.